Clinical Trials Logo
  1. Home
  2. Vitrectomy
  3. NCT00412958
  4. Details
NCT00412958 Clinical Trial

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

Vitrectomy Clinical Trial

Official title:
A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00412958
Other study ID # TG-MV-003
Secondary ID
Status Completed
Phase Phase 2
First received December 18, 2006
Last updated December 2, 2014
Start date December 2006
Est. completion date October 2008

Study information
Verified date April 2014
Source ThromboGenics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.

Recruitment information / eligibility
Status Completed
Enrollment 125
Est. completion date October 2008
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients in whom vitrectomy is indicated

Exclusion Criteria:

- Posterior Vitreous Detachment (PVD) present at baseline

- Vitreous hemorrhage

- Certain vitreoretinal conditions including proliferative disease, rhegmatogenous retinal detachment, and proliferative vitreoretinopathy (PVR)

- Have had a vitrectomy in the study eye at any time

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Ocriplasmin 25µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
• Ocriplasmin 75µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
• Ocriplasmin 125µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
• Placebo
Intravitreal injection of placebo

Locations
Country Name City State
United States Mailing add: New England Eye Center - Tufts Boston Massachusetts
United States Rush University Med. Ctr Chicago Illinois
United States Duke Eye Center Durham North Carolina
United States National Ophtlamic Research Institute Ft. Meyers Florida
United States Vitreoretinal Consultants Houston Texas
United States VMR Institute Huntington Beach California
United States Retina Association of Cleveland Lakewood Ohio
United States Jules Stein Eye Institute/UCLA Los Angeles California
United States Valley Retina Institute, P.A. McAllen Texas
United States Vitroretinal Surgery, PA Minneapolis Minnesota
United States Vanderbilt Eye Institute Nashville Tennessee
United States Retina Vitreous Centre, PA New Brunswick New Jersey
United States Columbia University - Harkness Eye Institute New York New York
United States Retina Vitreous Surgeons of Central NY New York New York
United States Allegheny Ophthalmic & Orbital Associates, P.C. Pittsburgh Pennsylvania
United States Retinal Consultants of San Diego Poway California
United States Associated Retinal Consultants, P.C. Royal Oak Michigan
United States Retinal Consultants Medical Group Sacramento California
United States Retina Centers, P.C. Tucson Arizona
United States Center for Retina and Macular Disease Winter Haven Florida

Sponsors (1)
Lead Sponsor Collaborator
ThromboGenics

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect The primary efficacy endpoint was the proportion of patients achieving total PVD without creation of an anatomical defect (ie, retinal hole, retinal detachment) based on surgeon visualization at the beginning of vitrectomy prior to suction or any other mechanical intervention. Day 7 No
See also
  Status Clinical Trial Phase
Terminated NCT04409808 - IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device. N/A
Active, not recruiting NCT04566237 - Objective Measurements of the Opacification of the Lens After Vitrectomy N/A
Completed NCT00532415 - Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy Phase 3
Completed NCT04076072 - Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe N/A
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Completed NCT00927628 - Macular Hole Reopening N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Terminated NCT01023009 - Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion
Completed NCT00737022 - Macular Appearance After Diabetic Vitrectomy N/A
Completed NCT02644694 - PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Phase 1
Completed NCT03902795 - Functional and Morphological Results of Rhegmatogenous Retinal Detachment Treated With Vitrectomy
Completed NCT01319318 - Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy N/A
Not yet recruiting NCT04346095 - Oral Sedation in Vitreoretinal Surgery Phase 4
Completed NCT01159665 - The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) Phase 2
Completed NCT00685490 - Vitrectomy for Branch Retinal Vein Occlusion N/A
Completed NCT05446948 - Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy N/A
Completed NCT05710458 - Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter N/A
Terminated NCT02995746 - Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane N/A
Completed NCT03701542 - The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole.